Xvivo Perfusion AB (publ) reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was SEK 210.35 million compared to SEK 154.57 million a year ago. Net income was SEK 27.19 million compared to SEK 6.89 million a year ago. Basic earnings per share from continuing operations was SEK 0.86 compared to SEK 0.23 a year ago. Diluted earnings per share from continuing operations was SEK 0.86 compared to SEK 0.23 a year ago.
For the six months, sales was SEK 396.37 million compared to SEK 295.19 million a year ago. Net income was SEK 49.98 million compared to SEK 21.06 million a year ago. Basic earnings per share from continuing operations was SEK 1.59 compared to SEK 0.71 a year ago. Diluted earnings per share from continuing operations was SEK 1.59 compared to SEK 0.71 a year ago.